Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director | May 18, 2024 | May 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date May 18, 2024 · Filed May 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-18 transaction · row 1
1 source rowRow 1 · 2024-05-18 · Gift · Disposed 2,927 · Balance 0 F1: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 22,575 |
Reported balance
After 2024-05-18 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-05-18 · Gift · Acquired 2,927 · Balance 22,575 F1: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units. F2: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units.
F2: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 12, 2019 Filed Dec 17, 2019 02:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,801 | $202.99 | $365,590.93 |
DisclosureSEC source: 0001093557-19-000258 · edgardoc.xml · nonDerivative · entry 2 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,166 F1 · shares: On September 13, 2019, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $202.71 to $203.69. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:16 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,299 | $202.22 | $464,909.99 |
DisclosureSEC source: 0001093557-19-000258 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 17,967 F1 · shares: On September 13, 2019, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $201.68 to $202.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 23:59 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 2,613 | $0.00 | $2.61 |
DisclosureSEC source: 0001093557-19-000151 · wf-form4_155969275804718.xml · nonDerivative · entry 2 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,613 F2 · shares: The RSU Award was granted on May 31, 2019 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2020 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 2,613 restricted stock units which were granted on May 31, 2019 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2020 Annual Meeting. Read SEC document |
| May 30, 2019 Filed Jun 4, 2019 23:59 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 3,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000151 · wf-form4_155969275804718.xml · nonDerivative · entry 3 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 20,266 F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units. F4 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. F4 · ownership.nature: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| May 30, 2019 Filed Jun 4, 2019 23:59 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 3,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000151 · wf-form4_155969275804718.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, upon vesting of previously awarded restricted stock units. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 23:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,343 | $142.83 | $763,154.58 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 5 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 16,817 F4 · shares: On December 12, 2018, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F7 · price: This transaction was executed in multiple trades at prices ranging from $142.51 to $143.34. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 23:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,558 | $142.07 | $505,470.83 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 4 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 22,160 F4 · shares: On December 12, 2018, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $141.51 to $142.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| January 14, 2019 Filed Jan 16, 2019 23:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 1,730 | $141.16 | $244,201.44 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 3 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 25,718 F4 · shares: On December 12, 2018, Ms. Kahn adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Kahn. The exercise and sale of shares set forth above were pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $140.51 to $141.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| June 01, 2018 Filed Jun 27, 2018 00:13 UTC Amendment | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 3,449 | $0.00 | $3.45 |
DisclosureSEC source: 0001093557-18-000137 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,449 F1 · shares: The RSU Award was granted on June 1, 2018 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2019 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. commom stock upon settlement. Read SEC document |
| June 01, 2018 Filed Jan 16, 2019 23:08 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 4,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 2 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 27,448 F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. F3 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| June 01, 2018 Filed Jan 16, 2019 23:08 UTC | DEXCOM INC DXCM · Entity 3114 | OtherCommon Stock | 4,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-19-000012 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,449 F1 · shares: Shares were transferred from direct ownership to ownership under the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. F2 · balance_after: Represents 3,449 unvested restricted stock units which were granted on June 1, 2018 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2019 Annual Meeting. Read SEC document |
| May 31, 2018 Filed Jun 5, 2018 00:00 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 3,457 | $0.00 | $3.46 |
DisclosureSEC source: 0001093557-18-000111 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,810 F1 · security: Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. commom stock upon settlement. F2 · shares: The RSU Award was granted on May 31, 2018 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2019 Annual Meeting. F3 · balance_after: Represents 7,810 unvested restricted stock units, 4,353 of which were granted on June 1, 2017 and shall vest on June 1, 2018 and 3,457 of which were granted on May 31, 2018 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2019 Annual Meeting. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 00:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $54.58 | $163,727.10 |
DisclosureSEC source: 0001093557-17-000227 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 23,095 F1 · price: This transaction was executed in multiple trades at prices ranging from $54.54 to $54.63. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| June 01, 2017 Filed Jun 6, 2017 00:50 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 4,353 | $0.00 | $4.35 |
DisclosureSEC source: 0001093557-17-000148 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,353 F1 · shares: Share units are restricted and subject to vesting in one annual installment from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 22:04 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,000 | $77.36 | $232,080.00 |
DisclosureSEC source: 0001093557-17-000085 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 21,304 F1 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| September 12, 2016 Filed Sep 15, 2016 00:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,000 | $92.90 | $464,511.50 |
DisclosureSEC source: 0001093557-16-000702 · edgardoc.xml · nonDerivative · entry 2 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 24,304 F3 · price: This transaction was executed in multiple trades at prices ranging from $92.90 to $92.95. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F4 · balance_after: Shares are held by the Barbara Kahn TTEE Barbara Kahn Rev TRT DTD 6/26/96 & Robert Meyer TTEE Robert Meyer Rev Trst DTD 6/26/96, with respect to which the reporting person is a trustee. Read SEC document |
| May 08, 2014 Filed Sep 15, 2016 00:44 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,500 | $30.11 | $225,854.25 |
DisclosureSEC source: 0001093557-16-000702 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,791 F1 · shares: Inadvertently filed late due to an administrative error. F2 · balance_after: Included in this number are 4,791 unvested restricted stock units which were granted on May 25, 2016 and shall vest on May 25, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.